ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

KRAS G12D Inhibitor VS-7375

Also written as “GFH375”, “VS-7375” and “GFH375 + Cetuximab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Pancreatic Neoplasms · Colorectal Neoplasms, led by 2 companies.

Drug pageKRAS G12D Inhibitor VS-7375: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 20, 202512 company-led studies, 11 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Genfleet Therapeutics (Shanghai)87 open or runningphase 3since Nov 20, 2025Jul 8, 2024Apr 30, 2027phase 2 · NCT07554859
Verastemits history only44 open or runningphase 2since May 26, 2025May 26, 2025Jun 2027phase 2 · NCT07659782

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Genfleet Therapeutics (Shanghai) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2024First study: phase 2 study in KRAS G12D MutationsFirst studyNCT06500676 · 407 planned · China
  2. Jun 3, 2025Phase 2 study in Pancreatic NeoplasmsNCT07026916
  3. Nov 14, 2025Phase 2 study in Colorectal NeoplasmsNCT07259590 · 126 planned · China
  4. Nov 20, 2025Phase 3 study in Pancreatic NeoplasmsPhase 3 reachedNCT07262567 · 320 planned · China
  5. Apr 21, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07554859 · 90 planned · China
  6. Jun 15, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07668752 · 300 planned · China
  7. Aug 10, 2026Phase 2 study in Pancreatic NeoplasmsNCT07784374 · 120 planned · China
  8. Oct 18, 2026Phase 3 study in Colorectal NeoplasmsNCT07913360 · 368 planned

Ahead

  1. Apr 30, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07554859
  2. Jun 2027Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07262567
  3. Jul 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07259590
  4. Jul 31, 2028Primary completion: phase 2 study in KRAS G12D MutationsNCT06500676

TargetBeta

KRAS →read by rule
“An orally bioavailable non-covalent small molecule inhibitor of both the active, guanosine triphosphate (GTP)-bound form and the inactive, guanosine diphosphate (GDP)-bound form of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36
opnurasibruleNovartisphase 35

Studies

All 8 Genfleet Therapeutics (Shanghai) leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07913360Colorectal Neoplasms3Not yet recruitingNov 2028368
NCT07784374Pancreatic Neoplasms · China2RecruitingAug 31, 2028120
NCT07668752Carcinoma, Non-Small-Cell Lung · China3RecruitingJun 30, 2030300
NCT07554859Carcinoma, Non-Small-Cell Lung · China2Not yet recruitingApr 30, 202790
NCT07262567Pancreatic Neoplasms · China3RecruitingJun 2027320
NCT07259590Colorectal Neoplasms · China2RecruitingJul 2027126
NCT07026916Pancreatic Neoplasms2WithdrawnAug 20270
NCT06500676KRAS G12D Mutations · China2RecruitingJul 31, 2028407

How it is read

Names in the registry

  • “GFH375”, 7 entries
  • “VS-7375”, 4 entries
  • “GFH375 + Cetuximab”, 1 entry
  • “ArmA:GFH375”, 1 entry
  • “Arm B:GFH375”, 1 entry

Codes read as this program: GFH375.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.